Genome Medicine


Review

Retinitis pigmentosa and allied conditions today: a paradigm of translational research

Carmen Ayuso1* and Jose M Millan2

Author Affiliations

1 Department of Medical Genetics, IIS-Fundación Jiménez Díaz/CIBERER, Av/Reyes Católicos no. 2; 28040, Madrid, Spain

2 Unidad de Genética, Hospital Universitario La Fe/CIBERER, Avda. Campanar, 21, 46009 Valencia, Spain

For all author emails, please log on.

Genome Medicine 2010, 2:34 doi:10.1186/gm155

Published: 27 May 2010

Abstract

Monogenic human retinal dystrophies are a group of disorders characterized by progressive loss of photoreceptor cells leading to visual handicap. Retinitis pigmentosa is a type of retinal dystrophy where degeneration of rod photoreceptors occurs at the early stages. At present, there are no available effective therapies to maintain or improve vision in patients affected with retinitis pigmentosa, but post-genomic studies are allowing the development of potential therapeutic approaches. This review summarizes current knowledge on genes that have been identified to be responsible for retinitis pigmentosa, the involvement of these genes in the different forms of the disorder, the role of the proteins encoded by these genes in retinal function, the utility of genotyping, and current efforts to develop novel therapies.